Researchers examined whether adjunctive gabapentin or memantine and standard treatment with a selective serotonin-reuptake inhibitor (SSRI) might lead to further improvements in patients with OCD.
A brain stimulation device to treat OCD has received approval for marketing by the US Food and Drug Administration.
These results identify several predictive factors for remission in children with OCD and may be useful for clinicians in tailoring their treatment approach, although the impact of adjunctive d-cycloserine requires further investigation.
Family history of OCD and the presence of tics may be important considerations for initial choice of treatment.
The risk of any mental disorder was increased for individuals with a positive streptococcal test, especially for OCD and tic disorders
DCS shows a small augmentation effect on exposure-based therapy.
Despite intense research efforts and recent advances in understanding the condition, the exact etiology of OCD remains largely undefined.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Panel Recommends Earlier Body Weight Monitoring in Use of Mood Stabilizers
- Nondaily Cigarette Use Increasing Among Individuals With Mental Health, Substance Use Disorders
- Cesarean Delivery, Early Childhood Antibiotic Use Not Associated With Risk for ADHD
- Uncertainty as a Form of Violence: Current Immigration Policy and Crisis
- FDA Gets Tough on Juul, Other Electronic Cigarette Makers